Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL therapy combined with chemoimmunotherapy in advanced non-small cell lung cancer
NL-OMON58965Phase 1Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2024
- Modality
- Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of GC101 TIL + pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Leiden University Medical Center. Started Nov 2024; status: recruiting.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON58965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58965.